Phase I/II ECHO-202/KEYNOTE-037: Safety of Epacadostat + Pembrolizumab in Solid Tumors

June 2-6, 2017; Chicago, Illinois
In a phase II expansion study, the combination had a low incidence of grade 3/4 adverse events across all tumor types evaluated.
Format: Microsoft PowerPoint (.ppt)
File Size: 443 KB
Released: June 5, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings